FDA cancels adcomm on Biohaven drug; Catalent lays off staff
Written by
BioPharma Dive
Published
0
comments
0
min
Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.